K\u0101 izv\u0113l\u0113ties NMN uztura bag\u0101tin\u0101t\u0101ju, kura kvalit\u0101te ir balst\u012bta uz dokumentiem, nevis m\u0101rketingu? Tirgus strauji aug \u2013 l\u012bdz ar to palielin\u0101s ar\u012b produktu skaits, kuru t\u012br\u012bba nav nek\u0101 pamatojama. Ja pl\u0101nojat ieg\u0101d\u0101ties NMN, \u0161\u012b rokasgr\u0101mata pal\u012bdz\u0113s saprast, uz ko piev\u0113rst uzman\u012bbu, ko jaut\u0101t un k\u0101 at\u0161\u0137irt dokument\u0113to kvalit\u0101ti no m\u0101rketinga.<\/p>\n\n\n\n
Ja v\u0113l neesat iepazinu\u0161ies ar NMN un NAD+ biolo\u0123iju \u2014 s\u0101ciet ar mums Visaptvero\u0161a NMN rokasgr\u0101mata<\/a>. Par blakuspar\u0101d\u012bb\u0101m un dro\u0161\u012bbu lasiet: NMN blakuspar\u0101d\u012bbas un dro\u0161\u012bba<\/a>.<\/em><\/p>\n\n\n\n \u0160is raksts ir informat\u012bvs. Purama.lt pied\u0101v\u0101tie NMN produkti saska\u0146\u0101 ar LR likumdo\u0161anu ir paredz\u0113ti studij\u0101m, zin\u0101tniskiem un laboratoriskiem p\u0113t\u012bjumiem (nevis cilv\u0113ku lieto\u0161anai).<\/em><\/p>\n\n\n\n NMN t\u012br\u012bba nor\u0101da, k\u0101da produkta da\u013ca ir faktiskais nikot\u012bnam\u012bda mononukleot\u012bds, nevis piemais\u012bjumi, mitrums vai sint\u0113zes blakusprodukti. Augstas kvalit\u0101tes NMN t\u012br\u012bbai j\u0101tiecas \u226599 %<\/strong>.<\/p>\n\n\n\n T\u012br\u012bba tiek p\u0101rbaud\u012bta div\u0101s galvenaj\u0101s metod\u0113s:<\/p>\n\n\n\n \u2714\ufe0f HPLC (Augstas veiktsp\u0113jas \u0161\u0137idrumu hromatogr\u0101fija)<\/strong> \u2014 augstspiediena \u0161\u0137idruma hromatogr\u0101fija. T\u0101 ir standarts farm\u0101cijas r\u016bpniec\u012bb\u0101: t\u0101 atdala savienojumus p\u0113c to \u0137\u012bmiskaj\u0101m \u012bpa\u0161\u012bb\u0101m un prec\u012bzi nosaka, k\u0101da da\u013ca parauga ir NMN. HPLC rezult\u0101ts ir skaitlis, ko varat atrast COA sertifik\u0101t\u0101 \u2014 piem\u0113ram, \u201eNMN purity: 99,8 % (by HPLC)\u201d.<\/p>\n\n\n\n \u2714\ufe0f NMR (Nukle\u0101r\u0101 magn\u0113tisk\u0101 rezonanse)<\/strong> \u2014 kodolmagn\u0113tisk\u0101 rezonansspektroskopija. NMR apstiprina molekulas strukt\u016bru \u2014 tas ir, pier\u0101da, ka viela patie\u0161\u0101m ir \u03b2-NMN, nevis cita l\u012bdz\u012bgas formulas molekula. Tas ir \u012bpa\u0161i svar\u012bgi, jo tirg\u016b ir sastopami produkti, kuru \u0137\u012bmisk\u0101 identit\u0101te neatbilst eti\u0137etei.<\/p>\n\n\n\n Ja produkta ra\u017eot\u0101js nor\u0101da t\u012br\u012bbu, bet neatkl\u0101j anal\u012bzes metodes<\/strong> \u2014 t\u0101 ir pirm\u0101 paz\u012bme, ka kaut kas nav k\u0101rt\u012bb\u0101.<\/p>\n\n\n\n COA (anal\u012bzes sertifik\u0101ts) ir neatkar\u012bgas laboratorijas vai ra\u017eot\u0101ja kvalit\u0101tes kontroles dokuments, kur\u0101 sniegti konkr\u0113tas partijas anal\u012b\u017eu rezult\u0101ti. \u0160eit ir lietas, kuras v\u0113rts p\u0101rbaud\u012bt:<\/p>\n\n\n\n \u2714\ufe0f Partijas numurs (Lot\/Batch number)<\/strong> \u2014 katrai ra\u017eo\u0161anas partijai vajadz\u0113tu b\u016bt unik\u0101lam identifikatoram. Ja COA nav partijas numura vai viens un tas pats sertifik\u0101ts tiek izmantots visiem produktiem \u2014 tas nav \u012bsts COA.<\/p>\n\n\n\n \u2714\ufe0f T\u012br\u012bba un metode<\/strong> \u2014 ie\u0161kokite konkre\u010dios eilut\u0117s, piem\u0113ram, \u201eAssay (by HPLC): \u226599,0 %\u201d vai \u201eNMN content: 99,8 %\u201d. Svar\u012bgi, lai tiktu nor\u0101d\u012bts ar\u012b anal\u012bzes metode<\/strong> (HPLC, UV, titr\u0113\u0161ana).<\/p>\n\n\n\n \u2714\ufe0f Prieda vielas un smagie met\u0101li<\/strong> \u2014 labas COA nor\u0101da smago met\u0101lu (svins, dz\u012bvsudrabs, kadmijs, ars\u0113ns) l\u012bmeni. Standarta ierobe\u017eojumi: Pb <0,5 ppm, Hg <0,1 ppm, As <0,5 ppm, Cd <0,5 ppm.<\/p>\n\n\n\n \u2714\ufe0f Mikrobiolo\u0123iskie r\u0101d\u012bt\u0101ji<\/strong> \u2014 kop\u0113jais mikroorganismu skaits, raugi, pel\u0113jumi, E. coli, salmonellas. Tas apliecina, ka produkts tika ra\u017eots un uzglab\u0101ts higi\u0113niski.<\/p>\n\n\n\n \u2714\ufe0f Tre\u0161\u0101s puses test\u0113\u0161ana<\/strong> \u2014 Vai COA izdevis pats ra\u017eot\u0101js, vai neatkar\u012bga akredit\u0113ta laboratorija? Neatkar\u012bga test\u0113\u0161ana ir augst\u0101ks uzticam\u012bbas standarts.<\/p>\n\n\n\n DoNotAge<\/a> Kiekviena partija tiekta su partijas numur\u0113to anal\u012bzes sertifik\u0101ta (CoA), kas ietver HPLC t\u012br\u012bbas, smago met\u0101lu un mikrobiolo\u0123iskos datus. Sertifik\u0101tus var apskat\u012bt produkta lap\u0101 vai piepras\u012bt.<\/p>\n\n\n\n Uthever\u00ae ir patent\u0113ta \u03b2-NMN sast\u0101vda\u013ca, ko ra\u017eo EffePharm (\u0160anhaja). K\u0101 tas at\u0161\u0137iras no \u201egenerisk\u0101\u201d NMN?<\/p>\n\n\n\n \u2714\ufe0f Kl\u012bniski p\u0101rbaud\u012bts<\/strong> \u2014 Uthever\u00ae ir vien\u012bg\u0101 NMN sast\u0101vda\u013ca, kas tika izmantota daudzcentru, randomiz\u0113t\u0101, dubultakl\u0101, placebo kontrol\u0113t\u0101 cilv\u0113ku p\u0113t\u012bjum\u0101 (Huang, 2022. g., Frontiers in Aging<\/em>. Izmekl\u0113juma laik\u0101 66 veseli 40\u201365 gadus veci dal\u012bbnieki 60 dienu laik\u0101 lietoja 300 mg NMN dien\u0101 \u2014 seruma NAD+\/NADH l\u012bmenis palielin\u0101j\u0101s par 38 % nek\u0101 s\u0101kum\u0101, sal\u012bdzinot ar 14,3 % placebo grup\u0101.<\/p>\n\n\n\n \u2714\ufe0f Ra\u017eo\u0161ana atbilsto\u0161i USP standartiem<\/strong> \u2014 EffePharm ra\u017eo\u0161ana atbilst Amerikas Savienoto Valstu farmakopejas (USP) standartiem, savuk\u0101rt kvalit\u0101tes kontrole tiek veikta atbilsto\u0161i GMP un ISO9001 pras\u012bb\u0101m.<\/p>\n\n\n\n \u2714\ufe0f Struktur\u0101l\u0101 verifik\u0101cija<\/strong> \u2014 katra Uthever\u00ae partija tiek p\u0101rbaud\u012bta ar HPLC, NMR un LC-MS (\u0161\u0137idrumu hromatogr\u0101fijas-masu spektrometrijas) metod\u0113m, apstiprinot gan t\u012br\u012bbu, gan molekulas identit\u0101ti.<\/p>\n\n\n\n \u2714\ufe0f ES regulat\u012bvais ce\u013c\u0161<\/strong> \u2014 Uthever\u00ae ir pirm\u0101 NMN sast\u0101vda\u013ca, kas veiksm\u012bgi iztur\u0113jusi EFSA publisko apsprie\u0161anu un pa\u0161laik atrodas riska nov\u0113rt\u0113\u0161anas stadij\u0101 attiec\u012bb\u0101 uz jauno p\u0101rtikas produktu statusu Eiropas Savien\u012bb\u0101.<\/p>\n\n\n\n Vai \u201egeneriskais\u201d NMN ir slikts?<\/strong> Neb\u016btina \u2014 \u0137\u012bmiski t\u012brs NMN ir NMN neatkar\u012bgi no z\u012bmola. Tom\u0113r at\u0161\u0137ir\u012bba ir patumam\u012bba<\/strong>: patented source ensures that the substance you are consuming is ta pati<\/strong>, kas tika izm\u0113\u0123in\u0101ts kl\u012bniskos p\u0113t\u012bjumos, nevis \u201el\u012bdz\u012bgs\u201d produkts no nezin\u0101mas r\u016bpn\u012bcas.<\/p>\n\n\n\n \u2192 DoNotAge NMN kapsulas (Uthever\u00ae 99,8 %)<\/a> \u2014 tie\u0161i t\u0101s pa\u0161as z\u0101les k\u0101 kl\u012bniskajos p\u0113t\u012bjumos.<\/p>\n\n\n\n No kvalit\u0101tes viedok\u013ca abas formas var b\u016bt l\u012bdzv\u0113rt\u012bgas \u2013 at\u0161\u0137ir\u012bba ir praktiskaj\u0101 \u0113rt\u012bb\u0101 un doz\u0113\u0161anas elast\u012bb\u0101.<\/p>\n\n\n\n \u2714\ufe0f Milti<\/strong> \u2014 \u013cauj br\u012bvi regul\u0113t devu (piem\u0113ram, s\u0101kot no 250 mg un palielinot l\u012bdz 500\u2013600 mg). Piem\u0113rots sublingv\u0101lam lieto\u0161anai (zem m\u0113les), kad NMN uzs\u016bcas caur mutes g\u013cot\u0101du. Pulvera veid\u0101 nav kapsulas apvalka, pildvielu vai papildu sast\u0101vda\u013cu \u2014 t\u0101 ir visatt\u012br\u0101k\u0101 forma.<\/p>\n\n\n\n \u2192 DoNotAge NMN pulveris (99,8 % t\u012br\u012bba)<\/a> \u2014 br\u012bv\u0101 deva, piem\u0113rota sublingv\u0101lu lieto\u0161anai.<\/p>\n\n\n\n \u2714\ufe0f Kapsulas<\/strong> \u2014 \u0113rt\u0101kas ikdienas lieto\u0161anai, \u012bpa\u0161i ce\u013cojot. Prec\u012bza, jau izm\u0113r\u012bta deva (piem\u0113ram, 500 mg). Svar\u012bgi izv\u0113l\u0113ties kapsulas ar augalu valgu apvalki<\/strong> (HPMC\/hipromeloze) un bez liekiem pildviel\u0101m (kr\u0101sviel\u0101m, konservantiem).<\/p>\n\n\n\n Par liposom\u0101lo NMN:<\/strong> 2025. gad\u0101 veikts jap\u0101\u0146u p\u0113t\u012bjums par\u0101d\u012bja, ka liposom\u0101l\u0101 forma pan\u0101ca augst\u0101ku NAD+ koncentr\u0101ciju nek\u0101 standarta peror\u0101l\u0101 forma. Tom\u0113r \u0161is p\u0113t\u012bjums bija mazs, un standarta peror\u0101l\u0101 NMN forma cilv\u0113ku p\u0113t\u012bjumos ar\u012b ticami paaugstin\u0101ja NAD+ l\u012bmeni. Kam\u0113r nav vair\u0101k sal\u012bdzino\u0161u RCT, liposom\u0101lais NMN joproj\u0101m ir \u201esolo\u0161s, bet v\u0113l nav pietiekami pier\u0101d\u012bts\u201d papildin\u0101jums.<\/p>\n\n\n\n Zinot \u0161os krit\u0113rijus, NMN izv\u0113le k\u013c\u016bst vienk\u0101r\u0161\u0101ka. Tirg\u016b ir simtiem NMN produktu. L\u016bk, pieci bie\u017e\u0101kie br\u012bdin\u0101juma sign\u0101li:<\/p>\n\n\n\n \u2714\ufe0f Nav pieejama anal\u012bzes kvalit\u0101tes sertifik\u0101ta (COA) inform\u0101cija vai anal\u012bzes kvalit\u0101tes sertifik\u0101t\u0101 (COA) nav partijas numura<\/strong> \u2014ja ra\u017eot\u0101js nevar uzr\u0101d\u012bt konkr\u0113tas partijas sertifik\u0101tu, nav iesp\u0113jas p\u0101rbaud\u012bt, kas paties\u012bb\u0101 atrodas produkta iek\u0161pus\u0113.<\/p>\n\n\n\n \u2714\ufe0f Par zemu cenu<\/strong> \u2014 farmaceitiskas NMN ra\u017eo\u0161anas kvalit\u0101te prasa zin\u0101mas izmaksas. Ja produkta cena ir vair\u0101kas reizes zem\u0101ka par tirgus vid\u0113jo, ir ticams, ka tiek taup\u012bts uz t\u012br\u012bbu, test\u0113\u0161anu vai apst\u0101k\u013ciem.<\/p>\n\n\n\n \u2714\ufe0f \u201ePatent\u0113ts mais\u012bjums\u201d bez sast\u0101vda\u013cu deta\u013c\u0101m<\/strong> \u2014 ja uzl\u012bm\u0113 ir nor\u0101d\u012bta \u201eproprietary blend\u201d un nav redzams prec\u012bzs NMN daudzums miligramos \u2014 j\u016bs nezin\u0101t, cik daudz NMN paties\u012bb\u0101 sa\u0146emat.<\/p>\n\n\n\n \u2714\ufe0f Drosm\u012bgi apgalvojumi bez avotiem<\/strong> \u2014 ja produkts sola \u201eatjauno\u0161anu\u201d, \u201edz\u012bves pagarin\u0101\u0161anu\u201d vai \u201egarant\u0113tu efektu\u201d, bet nenor\u0101da nek\u0101dus p\u0113t\u012bjumus \u2014 tas ir m\u0101rketings, ne zin\u0101tne. Vair\u0101k par to: NMN m\u012bti: 7 popul\u0101r\u0101kie apgalvojumi un pier\u0101d\u012bjumi par tiem<\/a>.<\/p>\n\n\n\n \u2714\ufe0f Nav nor\u0101d\u012bta izcelsmes valsts un standarti<\/strong> \u2014 labs ra\u017eot\u0101js publiski nor\u0101da, p\u0113c k\u0101diem standartiem (GMP, ISO) un kur\u0101 valst\u012b ra\u017eo produktu.<\/p>\n\n\n\n NMN regul\u0113jums pasaul\u0113 strauji main\u0101s. L\u016bk, aktu\u0101l\u0101k\u0101 situ\u0101cija 2026. gad\u0101:<\/p>\n\n\n\n \u2714\ufe0f Eiropas Savien\u012bba<\/strong> \u2014 NMN klasific\u0113ti k\u0101 Jauni p\u0101rtikas produkti<\/strong> saska\u0146\u0101 ar Regulu (ES) 2015\/2283. Tas noz\u012bm\u0113, ka pirms NMN ofici\u0101las tirdzniec\u012bbas k\u0101 uztura bag\u0101tin\u0101t\u0101ja Eiropas Savien\u012bb\u0101 ir nepiecie\u0161ams EFSA dro\u0161\u012bbas nov\u0113rt\u0113jums un Eiropas Komisijas at\u013cauja. L\u012bdz 2026. gada s\u0101kumam EFSA bija sa\u0146\u0113mis 6 pieteikumus par NMN k\u0101 jauna p\u0101rtikas veida statusu. Divi no tiem (tostarp Uthever\u00ae NMN) jau ir izg\u0101ju\u0161i publisku apsprie\u0161anu un atrodas riska nov\u0113rt\u0113\u0161anas posm\u0101. Ofici\u0101ls apstiprin\u0101jums pagaid\u0101m nav.<\/p>\n\n\n\n \u2714\ufe0f ASV<\/strong> \u2014 2025. gada 2. decembr\u012b P\u0101rtikas un z\u0101\u013cu administr\u0101cija (FDA) ofici\u0101li apstiprin\u0101ja NMN k\u0101 likum\u012bgu uztura bag\u0101tin\u0101t\u0101ju sast\u0101vda\u013cu (NDI statuss), atsaucot 2022. gad\u0101 noteikto aizliegumu. NMN tagad tiek leg\u0101li p\u0101rdots ASV k\u0101 uztura bag\u0101tin\u0101t\u0101js.<\/p>\n\n\n\n \u2714\ufe0f Lietuva<\/strong> \u2014 saska\u0146\u0101 ar Lietuvas Republikas ties\u012bbu aktiem NMN (nikot\u012bnam\u012bda mononukleot\u012bds) ir \u0137\u012bmiska viela, kas nav piem\u0113rota lieto\u0161anai cilv\u0113kiem. NMN produkti Lietuv\u0101 tiek klasific\u0113ti k\u0101 paredz\u0113ti studij\u0101m, zin\u0101tniskai un laboratoriskai izp\u0113tei.<\/p>\n\n\n\n \u2714\ufe0f Jap\u0101na ir Dienvidkoreja<\/strong> \u2014 NMN likum\u0101 ir pieejams p\u0101rdo\u0161an\u0101 k\u0101 uztura bag\u0101tin\u0101t\u0101js, ar labi att\u012bst\u012btu pat\u0113r\u0113t\u0101ju tirgu.<\/p>\n\n\n\n \u0160\u012b situ\u0101cija par\u0101da, k\u0101p\u0113c produktu izcelsme un dokument\u0101cija<\/strong> ir ir ir ir svarb\u016bs: pasirinkdami NMN no ra\u017eot\u0101ja, kas akt\u012bvi cen\u0161as ieg\u016bt ofici\u0101lu ES jaunuz\u0146\u0113mumu p\u0101rtikas statusu (k\u0101 Uthever\u00ae\/EffePharm), j\u016bs izv\u0113laties produktu, kura kvalit\u0101tes dati jau ir iesniegti EFSA izv\u0113rt\u0113\u0161anai.<\/p>\n\n\n\n Pieprasiet no ra\u017eot\u0101ja COA (anal\u012bzes sertifik\u0101tu) ar attiec\u012bg\u0101s partijas numuru, HPLC t\u012br\u012bbu \u226599 %, smago met\u0101lu un mikrobiolo\u0123iskajiem datiem. Ja ra\u017eot\u0101js nevar vai nev\u0113las to iesniegt \u2014 t\u0101 ir nopietna br\u012bdin\u0101juma z\u012bme.<\/p>\n\n\n\n Uthever\u00ae ir patent\u0113ta EffePharm ra\u017eot\u0101 preces z\u012bme, kas apz\u012bm\u0113 \u03b2-NMN. Tas ir vien\u012bgais NMN, kas tika izmantots daudzcentru, dubult-akl\u0101 kl\u012bniskaj\u0101 cilv\u0113ku p\u0113t\u012bjum\u0101 (Huang, 2022). Ra\u017eo\u0161ana atbilst USP, GMP un ISO9001 standartiem, t\u012br\u012bba >99,8 %.<\/p>\n\n\n\n Cena, bet reti. Farmaceitisk\u0101s kvalit\u0101tes NMN ra\u017eo\u0161anai, test\u0113\u0161anai (HPLC, NMR) un neatkar\u012bgai rev\u012bzijai ir sava cena. Ja produkta cena ir vair\u0101kas reizes zem\u0101ka par tirgus vid\u0113jo, ir v\u0113rts jaut\u0101t \u2014 uz k\u0101 tika ietaup\u012bts.<\/p>\n\n\n\n Kvalit\u0101te ir atkar\u012bga nevis no formas, bet gan no izejviel\u0101m un ra\u017eo\u0161anas standartiem. Pulveris \u013cauj regul\u0113t devu un lietot sublingv\u0101li. Kapsulas ir \u0113rt\u0101kas ikdien\u0101. Svar\u012bg\u0101kais ir tas, lai ab\u0101m form\u0101m b\u016btu COA un \u226599 % t\u012br\u012bba.<\/p>\n\n\n\n J\u0101 \u2014 NMN ir pieejams Lietuv\u0101. Saska\u0146\u0101 ar Lietuvas Republikas ties\u012bbu aktiem NMN produkti ir klasific\u0113ti k\u0101 paredz\u0113ti studij\u0101m, zin\u0101tniskajiem un laboratoriskajiem p\u0113t\u012bjumiem. ES l\u012bmen\u012b NMN joproj\u0101m gaida \"Novel Food\" apstiprin\u0101jumu.<\/p>\n\n\n\n Purama.lt<\/a> pied\u0101v\u0101 DoNotAge NMN produktus (pulveri un kapsulas) ar COA sertifik\u0101tiem, partijas izsekojam\u012bbu un \u226599,8 % t\u012br\u012bbu. Pieg\u0101de vis\u0101 Lietuv\u0101 \u2014 1\u20132 darba dienas.<\/p>\n\n\n\n Avoti:<\/strong><\/p>\n\n\n\n Huangs, H. (2022). Daudzcentru, randomiz\u0113ts, dubultaklapsu, paral\u0113lais, placebo kontrol\u0113ts p\u0113t\u012bjums Uthever (NMN papildin\u0101jums) efektivit\u0101tes un dro\u0161uma nov\u0113rt\u0113\u0161anai. Frontiers in Aging<\/em>, 3, 851698.<\/a> <\/p>","protected":false},"excerpt":{"rendered":" Kaip pasirinkti NMN papild\u0105, kurio kokyb\u0117 pagr\u012fsta dokumentais, o ne marketingu? Rinka auga spar\u010diai \u2014 kartu su ja auga ir produkt\u0173, kuri\u0173 grynumas niekuo nepagr\u012fstas. Jei planuojate \u012fsigyti NMN, \u0161is gidas pad\u0117s suprasti, \u012f k\u0105 \u017ei\u016br\u0117ti, ko klausti ir kaip atskirti dokumentuot\u0105 kokyb\u0119 nuo marketingo. Jei dar nesate susipa\u017ein\u0119 su NMN ir NAD+ biologija \u2014 […]<\/p>\n","protected":false},"author":38,"featured_media":47655,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[310],"tags":[],"class_list":["post-47144","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ilgaamziskumo-gidas"],"acf":[],"_links":{"self":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/posts\/47144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/comments?post=47144"}],"version-history":[{"count":0,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/posts\/47144\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/media\/47655"}],"wp:attachment":[{"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/media?parent=47144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/categories?post=47144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/purama.lt\/lv\/wp-json\/wp\/v2\/tags?post=47144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Grynumo standartai: ko noz\u012bm\u0113 \u201e99 %\u201d un k\u0101 tas tiek p\u0101rbaud\u012bts<\/h2>\n\n\n\n
K\u0101 izv\u0113l\u0113ties NMN p\u0113c COA: 5 lietas, kuras p\u0101rbaud\u012bt<\/h2>\n\n\n\n
Uthever\u00ae pret visko\u017eenu NMN: k\u0101 at\u0161\u0137iras patent\u0113tais avots<\/h2>\n\n\n\n
NMN forms: pulveris pret kapsul\u0101m<\/h2>\n\n\n\n
Sarkanie karogi: 5 paz\u012bmes, ka NMN produkts rada jaut\u0101jumus<\/h2>\n\n\n\n
NMN tiesin\u0117 pad\u0117tis: ES, JAV ir Lietuva 2026<\/h2>\n\n\n\n
Bie\u017e\u0101k uzdotie jaut\u0101jumi (FAQ)<\/h2>\n\n\n\n
K\u0101 p\u0101rbaud\u012bt, vai NMN produkts patie\u0161\u0101m ir kvalitat\u012bvs?<\/h3>\n\n\n\n
Kas ir Uthever\u00ae NMN un k\u0101 tas at\u0161\u0137iras?<\/h3>\n\n\n\n
Vai l\u0113ts NMN var b\u016bt kvalitat\u012bvs?<\/h3>\n\n\n\n
NMN pulveris vai kapsulas \u2014 kas ir kvalitat\u012bv\u0101ks?<\/h3>\n\n\n\n
Vai NMN ir leg\u0101ls ieg\u0101d\u0101ties Lietuv\u0101?<\/h3>\n\n\n\n
Kur pirkti kokybi\u0161k\u0105 NMN Lietuvoje?<\/h3>\n\n\n\n
Yi, L. et al. (2023). \u03b2-NMN piedevas efektivit\u0101te un dro\u0161\u012bba veseliem pusm\u016b\u017ea pieaugu\u0161ajiem. Gerozin\u0101tne<\/em>, 45(1), 29\u201343.<\/a>
\u010cens, F. et al. (2024). Or\u0101l\u0101 NMN papildin\u0101\u0161anas ietekme uz glikozes un lip\u012bdu metabolismu: sistem\u0101tisks p\u0101rskats ar metaanal\u012bzi par KSP. Kritiskie p\u0101rskati p\u0101rtikas zin\u0101tn\u0113 un uztur\u0101<\/em>.<\/a>
Regula (ES) 2015\/2283 par jauniem p\u0101rtikas produktiem.<\/a><\/p>\n\n\n\n